The extract acknowledges scholarly engagement with the ERS/EULAR clinical practice guidelines for connective tissue disease–associated interstitial lung disease (CTD-ILD). It notes interest from J.R. Davidsen and colleagues concerning the guidelines recently published by ERS/EULAR. The authors express awareness of the rapidly evolving evidence base related to screening tools in rheumatoid arthritis–associated ILD (RA-ILD). The quoted text does not provide data on specific recommendations, outcomes, or methodologies, and it explicitly limits its content to recognition of discourse and the ongoing evolution of screening evidence in RA-ILD. Any conclusions about the guidelines’ content, validation, or applicability would require referring to the full guideline publications themselves. Given the brevity and extract nature, there is uncertainty regarding exact recommendations or changes in practice arising from these discussions. Clinicians should consult the complete ERS/EULAR CTD-ILD guidelines document for comprehensive guidance and for up-to-date screening approaches, noting that evidence in RA-ILD screening remains in flux according to the authors’ acknowledgment.
Extract We appreciate the interest and engagement from J.R. Davidsen and co-workers regarding the recently published European Respiratory Society (ERS)/European Alliance of Associations for Rheumatology (EULAR) clinical practice guidelines for connective tissue disease-associated interstitial lung disease (CTD-ILD) [1, 2]. We recognise the rapidly evolving evidence landscape for screening tools in rheumatoid arthritis-associated ILD (RA-ILD).